CC-93269
Drug
Celgene Corporation
Total Payments
$1.7M
Transactions
17
Doctors
3
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $1.6M | 11 | 3 |
| 2018 | $128,519 | 6 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.7M | 17 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma (CC-93269-MM-001) | Celgene Corporation | $1.6M | 3 |
| CC-93269-MM-001 - A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma | Celgene Corporation | $128,519 | 0 |
Top Doctors Receiving Payments for CC-93269
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Atlanta, GA | $1.7M | 14 |
| , MD | Internal Medicine | Seattle, WA | $935.00 | 1 |
| Luciano Costa | Hematology & Oncology | Birmingham, AL | $935.00 | 1 |
| , M.D | Internal Medicine | San Francisco, CA | $935.00 | 1 |
Ad
Manufacturing Companies
- Celgene Corporation $1.7M
Product Information
- Type Drug
- Total Payments $1.7M
- Total Doctors 3
- Transactions 17
About CC-93269
CC-93269 is a drug associated with $1.7M in payments to 3 healthcare providers, recorded across 17 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2018 to 2019. In 2019, $1.6M was paid across 11 transactions to 3 doctors.
The most common payment nature for CC-93269 is "Unspecified" ($1.7M, 100.0% of total).
CC-93269 is associated with 2 research studies, including "A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma (CC-93269-MM-001)" ($1.6M).